Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Lipton

Showing results (41-50 of 148) with videos related to

Pageof 15
Sort By:
Clinical Orthopaedics and Related Research|November 6, 2003
Biochemical markers and skeletal metastasesLaurence M Demers, Luis Costa, Allan Lipton
Breast Disease|December 7, 2011
Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?Allan Lipton, Luis Costa, Robert E Coleman
International Journal of Hematology|April 27, 2011
Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case seriesShanthi Sivendran, Harold Harvey, Allan Lipton, et al.
Clinical Orthopaedics and Related Research|November 6, 2003
Metastatic breast cancer: overview of treatmentS M Ali, H A Harvey, Allan Lipton
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?Julie R Gralow, Allan Lipton, Alison T Stopeck
Current Osteoporosis Reports|January 11, 2015
Antiresorptive therapy in the management of cancer treatment-induced bone lossAshwani Garg, Kim Leitzel, Suhail Ali, et al.
Critical Reviews in Oncology/Hematology|March 1, 2011
Anticancer evidence for zoledronic acid across the cancer continuumLuis Costa, Peter Harper, Robert E Coleman, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 9, 2008
Impact of skeletal complications on patients' quality of life, mobility, and functional independenceLuis Costa, Xavier Badia, Edward Chow, et al.
Clinical Medicine Insights. Oncology|August 31, 2012
Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumabAllan Lipton, Matthew R Smith, Georgiana K Ellis, et al.
Critical Reviews in Oncology/Hematology|September 18, 2010
Dosing of zoledronic acid throughout the treatment continuum in breast cancerPeyman Hadji, Michael Gnant, Matti Aapro, et al.
Pageof 15

Showing results (41-50 of 148) with videos related to

Sort By:
Pageof 15
Clinical Orthopaedics and Related Research|November 6, 2003
Biochemical markers and skeletal metastasesLaurence M Demers, Luis Costa, Allan Lipton
Breast Disease|December 7, 2011
Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?Allan Lipton, Luis Costa, Robert E Coleman
International Journal of Hematology|April 27, 2011
Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case seriesShanthi Sivendran, Harold Harvey, Allan Lipton, et al.
Clinical Orthopaedics and Related Research|November 6, 2003
Metastatic breast cancer: overview of treatmentS M Ali, H A Harvey, Allan Lipton
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?Julie R Gralow, Allan Lipton, Alison T Stopeck
Current Osteoporosis Reports|January 11, 2015
Antiresorptive therapy in the management of cancer treatment-induced bone lossAshwani Garg, Kim Leitzel, Suhail Ali, et al.
Critical Reviews in Oncology/Hematology|March 1, 2011
Anticancer evidence for zoledronic acid across the cancer continuumLuis Costa, Peter Harper, Robert E Coleman, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 9, 2008
Impact of skeletal complications on patients' quality of life, mobility, and functional independenceLuis Costa, Xavier Badia, Edward Chow, et al.
Clinical Medicine Insights. Oncology|August 31, 2012
Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumabAllan Lipton, Matthew R Smith, Georgiana K Ellis, et al.
Critical Reviews in Oncology/Hematology|September 18, 2010
Dosing of zoledronic acid throughout the treatment continuum in breast cancerPeyman Hadji, Michael Gnant, Matti Aapro, et al.
Pageof 15